Updating BRIUMVI U.S. net product revenue target to approximately $290 to $300 million for the full year 2024, prior guidance of $270 to $290 million for full year 2024
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- TG Therapeutics call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today
- TG Therapeutics Shareholders Back Growth at Annual Meeting
- TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference